Mn Services Vermogensbeheer B.V. Acquires 10,200 Shares of Boston Scientific Co. (NYSE:BSX)

Mn Services Vermogensbeheer B.V. grew its stake in shares of Boston Scientific Co. (NYSE:BSX) by 1.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 578,700 shares of the medical equipment provider’s stock after purchasing an additional 10,200 shares during the period. Mn Services Vermogensbeheer B.V.’s holdings in Boston Scientific were worth $51,689,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in the company. New York Life Investment Management LLC grew its stake in Boston Scientific by 1.2% in the 4th quarter. New York Life Investment Management LLC now owns 203,294 shares of the medical equipment provider’s stock valued at $18,158,000 after purchasing an additional 2,488 shares during the period. Cable Hill Partners LLC increased its holdings in Boston Scientific by 5.5% during the fourth quarter. Cable Hill Partners LLC now owns 6,209 shares of the medical equipment provider’s stock worth $555,000 after buying an additional 323 shares during the last quarter. Whipplewood Advisors LLC bought a new stake in Boston Scientific in the fourth quarter worth about $94,000. Oregon Public Employees Retirement Fund grew its position in shares of Boston Scientific by 0.3% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 126,369 shares of the medical equipment provider’s stock valued at $11,287,000 after acquiring an additional 360 shares during the period. Finally, Advisor OS LLC increased its stake in shares of Boston Scientific by 10.7% during the 4th quarter. Advisor OS LLC now owns 2,814 shares of the medical equipment provider’s stock worth $251,000 after purchasing an additional 272 shares during the last quarter. 89.07% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, EVP John Bradley Sorenson sold 1,201 shares of the firm’s stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $106.31, for a total transaction of $127,678.31. Following the sale, the executive vice president now owns 25,443 shares of the company’s stock, valued at $2,704,845.33. This trade represents a 4.51 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Daniel J. Brennan sold 15,087 shares of the stock in a transaction on Wednesday, February 12th. The shares were sold at an average price of $105.07, for a total value of $1,585,191.09. Following the sale, the chief financial officer now owns 241,451 shares of the company’s stock, valued at approximately $25,369,256.57. This represents a 5.88 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 144,305 shares of company stock valued at $14,954,985 over the last ninety days. 0.50% of the stock is owned by insiders.

Boston Scientific Price Performance

Shares of NYSE:BSX opened at $101.61 on Thursday. The firm has a market cap of $149.96 billion, a price-to-earnings ratio of 81.29, a P/E/G ratio of 2.79 and a beta of 0.80. The firm has a fifty day moving average price of $98.73 and a 200 day moving average price of $89.95. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.02 and a current ratio of 1.08. Boston Scientific Co. has a fifty-two week low of $65.52 and a fifty-two week high of $107.17.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share for the quarter, beating analysts’ consensus estimates of $0.65 by $0.05. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. As a group, sell-side analysts expect that Boston Scientific Co. will post 2.85 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms recently commented on BSX. Stifel Nicolaus upped their price objective on Boston Scientific from $100.00 to $115.00 and gave the company a “buy” rating in a research note on Thursday, February 6th. Citigroup upped their price objective on shares of Boston Scientific from $107.00 to $122.00 and gave the company a “buy” rating in a report on Thursday, February 6th. Raymond James lifted their price target on Boston Scientific from $119.00 to $122.00 and gave the company a “strong-buy” rating in a research report on Thursday, February 6th. Wells Fargo & Company raised their price target on shares of Boston Scientific from $100.00 to $118.00 and gave the company an “overweight” rating in a report on Thursday, February 6th. Finally, Royal Bank of Canada raised their price target on Boston Scientific from $105.00 to $116.00 and gave the stock an “outperform” rating in a research report on Thursday, February 6th. Two research analysts have rated the stock with a hold rating, twenty-one have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $107.39.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.